منابع مشابه
The Cardiovascular and Blood Pressure Effects and Safety of the SGLT2 Inhibitors
Type 2 diabetes mellitus is an independent risk factor for Cardiovascular Disease (CVD) and hypertension and patients with Type2 DM has a two-to four fold risk in developing CVD than nondiabetic persons [1]. For very long time, management of Type2 DM was focused on controlling blood glucose, since hyperglycemia has been associated with increased cardiovascular risk [2,3], but aggressive blood g...
متن کاملMechanism of Action of Sglt2-inhibitors
T2DM individuals manifest a 2-3 times greater risk of CV events compared to non-diabetics, and CV mortality is responsible for ~70% of total mortality. In T2DM patients without MI, risk of CV death is similar to individuals without diabetes with prior MI.1 Although hyperglycemia is a strong risk factor for microvascular complications, it is a weak risk factor for CV disease (CVD), and intervent...
متن کاملSGLT2 Inhibitors and the Diabetic Kidney.
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may have the potential to exert nephroprotectio...
متن کاملEuglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors.
Recently, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication that warns of an increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild to moderate glucose elevations (euglycemic DKA [euDKA]) associated with the use of all the approved sodium–glucose cotransporter 2 (SGLT2) inhibitors (1). This Communication was based on 20 clinical cases requiring...
متن کاملSGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Although cardiovascular (CV) mortality is the principal cause of death in individuals with type 2 diabetes (T2DM), reduction of plasma glucose concentration has little effect on CV disease (CVD) risk. Thus, novel strategies to reduce CVD risk in T2DM patients are needed. The recently published BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Diabetology
سال: 2016
ISSN: 2450-8187,2450-7458
DOI: 10.5603/dk.2016.0007